-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug ...

The price you pay for Lumryz may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost of ...

DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical ...

– Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – ...

DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has ...

Alkermes is positioned for significant growth through LUMRYZ’s potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ’s IH indication could drive incremental ...

With the launch risk dissipating, the legal risks take center stage as the main competitor Jazz Pharmaceuticals (JAZZ) is not giving up and is coming up with new ways of challenging Avadel and Lumryz.

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the ...

Based on the positive phase 3 results, Alkermes now plans to file for approval with the FDA by the end of 2026. (iStock/Getty Images Plus) Alkermes has chalked up a quick clinical win from its $2.37 ...

The cost of Lumryz can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Lumryz. As with all medications, the ...